PTHS Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagio…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […] | ||
 Pelthos (PTHS) Q2 2026 Earnings Call Transcript ZELSUVMI revenue jumped 45% as prescriber count surged and new PBM contracts drove adoption. | ||
 Pelthos Therapeutics Q2 Earnings Call Highlights Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment’s July 2025 commercial launch. The company also discussed an accounting restatement related to the fair-value measurement of convertible | ||
Pelthos Therapeutics Inc (PTHS) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as ... Strong prescription growth and expanding prescriber base drive momentum, while company navigates inventory adjustments and prepares for upcoming launches. | ||
 Pelthos Therapeutics Inc. Q2 2026 Earnings Call Summary Moby summary of Pelthos Therapeutics Inc.'s Q2 2026 earnings call | ||
 Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -119.21% and -2.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 This Biotech Dealmaker — Tied To Merck, Travere — Is In A Profit-Taking Zone Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. | ||